NervGen Pharma Corp. Common stock

NGEN | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.37

-$0.07 (-4.86%)

At close: Oct 30, 2026, 4:00 PM ET

$1.55

+$0.18 (+13.14%)

Pre-market: Nov 2, 2026, 4:01 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $147.31M

Enterprise Value $122.17M

Beta 0.73

Average Volume 574.87K

Shares Outstanding (Diluted) 92.44M

Shares Change YoY 28.47%

Institutional Ownership 12.97%

Exchange NASDAQ

ISIN CA64082X2032

Price Performance

Price Change 1M -28.3%

Price Change 3M -15.4%

Price Change 6M -63.8%

Price Change YTD -75.5%

Price Change 1Y N/A

Price Change 3Y N/A

Price Change 5Y N/A

1M CAGR (ann.) -33.2%

1Y CAGR (ann.) N/A

5Y CAGR (ann.) N/A

All-Time CAGR -72.2%

Valuation

PE Ratio -2.23

Forward PE N/A

PEG Ratio 0.02

Forward PEG -0.02

PS Ratio N/A

Forward PS N/A

PB Ratio 12.08

P/FCF Ratio -6.88

P/Adj. FCF Ratio -5.82

P/OCF Ratio -5.91

EV/Sales N/A

EV/EBIT -10.46

EV/EBITDA -10.52

EV/FCF -4.13

Earnings Yield -44.5%

FCF Yield -14.4%

Adj. FCF Yield -17.0%

Financial Health

Net Cash C$86.93M

Total Debt C$0

Cash & Short-Term Investments C$86.93M

Total Assets C$90.34M

Current Ratio 1.23

Quick Ratio 1.23

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt N/A

Interest Coverage 0.00

Altman Z-Score -1.24

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -18.2%

Returns

Return on Assets -74.8%

Return on Equity -1156.1%

Return on Invested Capital -219.9%

Return on Capital Employed -219.9%

Return on Tangible Assets -75.1%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -45.0%

EPS CAGR 5Y -21.7%

EPS CAGR 10Y N/A

FCF CAGR 3Y -45.1%

FCF CAGR 5Y -19.4%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 1

EPS Growth Next 3Y 24.7%

Revenue Growth Next 3Y N/A

Earnings Date Nov 12, 2026

EPS Estimate (next Q) -$0.07

EPS Growth Est (next Q) 141.3%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $12.00

Price Target Upside 775.9%

Cash Flow

Operating Cash Flow C$-29.6M

Free Cash Flow C$-29.6M

Adj. Free Cash Flow C$-34.99M

FCF Per Share -$0.32

OCF Per Share -$0.32

OCF/S Ratio 0.0%

Income Statement

Revenue C$0

Gross Profit C$-12.52K

Operating Income C$-38.06M

EBITDA C$-11.61M

Net Income C$-67.56M

EPS (Diluted) -$0.85

Revenue / Employee N/A

Profit / Employee $-8.44M

Employees 8